Skip to main content

COVALENT-112

A Phase 2 clinical trial for adults
with stage 3 Type 1 Diabetes

About COVALENT-112

What is the NCT number for COVALENT-112?

The National Clinical Trial reference number is: NCT06152042. 

When you talk with your doctor or clinical trial team member, please have the national trial reference number available. 

What does it mean to be randomized, double-blind, placebo-controlled study?

It means that 1 out of 3 patients will receive the BMF-219 at 100mg, 1 out of 3 patients will receive BMF-219 at 200mg, and 1 out of 3 patients will receive placebo. This allocation will be based on chance and neither the treating physician nor the patient will know their assignment during the treatment period. 

 

What does it mean to be open label study?

It means all patients will receive the BMF-219, the study drug and that the dose level will be pre-allocated. There will be no placebo and the allocation will not be based on chance. 

Will it cost me anything?

Study medication and study-related care will be provided at no cost.

Phase II Patient eligibility 

Age:
18 – 70 years
Sex:

All

Conditions:
Stage 3
Type 1 Diabete
s
  • Be 18 to 70 years of age
  • All sexes included
  • Diagnosed with Stage 3 Type 1 Diabetes

And also:

  • HbA1c ≥ 6.5% and ≤ 10% at screening
  • BMI ≤ 40 kg/m2

The science behind COVALENT-112

What is BMF-219?

BMF-219 is an investigational, orally bioavailable small molecule, which covalently binds to the scaffold protein menin, an important transcriptional regulator known to play a direct role in regulating beta cell growth.  

Contact us

Our clinical trials team will contact you shortly after your form submission.